Examination of the Hemoglobin, Albumin, Lymphocyte, and Platelet Score of Testicular Tumor: Comparison of Pre- and Postoperative and Non-Cancerous Patients

Abstract

Objective: To determine and compare the pre-and post-operative hemoglobin, albumin, lymphocyte, and platelet (HALP) scores of patients who underwent radical orchiectomy for testicular tumor based on pathology and stage with those of patients without a testicular tumor. Materials and Methods: One hundred nineteen patients diagnosed with testicular tumor between 2017 and 2022 were retrospectively analyzed. Patients’ pre- and post-op HALP, neutrophil-lymphocyte ratio, and platelet-lymphocyte ratio values were saved. In the control group, 100 varicocelectomy patients aged 19 to 56 between 2018 and 2022 were questioned. The data were analyzed based on pathology and stage; tumor patients were compared with the control group. Results: The tumor and control groups had mean ages of 31 and 30 years; the seminoma group had a pre-op HALP score of 59, while the mixed germ cell tumor (MGCT) group had a score of 55 (p=0.283). There was no statistical difference in HALP scores between pathological groups before and after surgery (p=0.327, 0.510). The testicular tumor group’s mean pre-op HALP value was 57.75, whereas the control group’s was 70.85 (p=0.000). There were 28 embryonal carcinomas among the 54 MGCT group patients. The pre-op and post-op HALP scores of both pathological groups were not significant (p=0.162, 0.104). Conclusion: The HALP score is an important parameter that is higher in testicular cancer patients than in non-cancerous patients. There was no statistically significant difference in HALP scores based on pathological subtype, tumor stage, or lymph node metastasis status.

Keywords

• biomarker
• hemoglobin
• albumin
• lymphocyte
• platelet (halp) score
• nomogram
• testicular cancer